AR127945A1 - PHARMACEUTICAL FORMULATIONS COMPRISING AN AMYLIN RECEPTOR AGONIST, A GLP-1 RECEPTOR AGONIST AND A CYCLODEXTRIN - Google Patents

PHARMACEUTICAL FORMULATIONS COMPRISING AN AMYLIN RECEPTOR AGONIST, A GLP-1 RECEPTOR AGONIST AND A CYCLODEXTRIN

Info

Publication number
AR127945A1
AR127945A1 ARP220103410A ARP220103410A AR127945A1 AR 127945 A1 AR127945 A1 AR 127945A1 AR P220103410 A ARP220103410 A AR P220103410A AR P220103410 A ARP220103410 A AR P220103410A AR 127945 A1 AR127945 A1 AR 127945A1
Authority
AR
Argentina
Prior art keywords
receptor agonist
glp
cyclodextrin
pharmaceutical formulations
amylin
Prior art date
Application number
ARP220103410A
Other languages
Spanish (es)
Inventor
Rosa Rebecca Erritze Hansen
Stig Christoffersen
Benjamin Kjeldsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to PCT/EP2023/058317 priority Critical patent/WO2023187067A1/en
Publication of AR127945A1 publication Critical patent/AR127945A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

En la presente descripción se describe una formulación farmacéutica líquida que comprende un agonista del receptor de amilina, un agonista del receptor de GLP-1 y una ciclodextrina que comprende sustituciones de hidroxipropilo. Dicha coformulación puede usarse para el tratamiento médico de sujetos con sobrepeso u obesidad, con o sin comorbilidades asociadas; diabetes, con o sin comorbilidades asociadas; enfermedades cardiovasculares, esteatohepatitis no alcohólica (NASH) y deterioro cognitivo, tal como el que provoca la enfermedad de Alzheimer.Described herein is a liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist and a cyclodextrin comprising hydroxypropyl substitutions. Said coformulation can be used for the medical treatment of overweight or obese subjects, with or without associated comorbidities; diabetes, with or without associated comorbidities; cardiovascular diseases, non-alcoholic steatohepatitis (NASH) and cognitive impairment, such as that caused by Alzheimer's disease.

ARP220103410A 2021-12-13 2022-12-13 PHARMACEUTICAL FORMULATIONS COMPRISING AN AMYLIN RECEPTOR AGONIST, A GLP-1 RECEPTOR AGONIST AND A CYCLODEXTRIN AR127945A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2023/058317 WO2023187067A1 (en) 2022-03-30 2023-03-30 Formulation method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21214004 2021-12-13
EP22191564 2022-08-22

Publications (1)

Publication Number Publication Date
AR127945A1 true AR127945A1 (en) 2024-03-13

Family

ID=84819844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103410A AR127945A1 (en) 2021-12-13 2022-12-13 PHARMACEUTICAL FORMULATIONS COMPRISING AN AMYLIN RECEPTOR AGONIST, A GLP-1 RECEPTOR AGONIST AND A CYCLODEXTRIN

Country Status (3)

Country Link
AR (1) AR127945A1 (en)
TW (1) TW202339788A (en)
WO (1) WO2023110833A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2007022518A2 (en) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
CN101605530A (en) * 2006-12-12 2009-12-16 安米林药品公司 Pharmaceutical preparation and preparation method thereof
SI2718316T1 (en) 2011-06-10 2020-03-31 Novo Nordisk A/S Polypeptides
EP3858373A1 (en) * 2020-01-31 2021-08-04 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
PE20231659A1 (en) 2020-12-18 2023-10-17 Novo Nordisk As COAGONISTS OF GLP-1 AND AMYLIN RECEPTORS

Also Published As

Publication number Publication date
WO2023110833A1 (en) 2023-06-22
TW202339788A (en) 2023-10-16

Similar Documents

Publication Publication Date Title
CL2021001332A1 (en) Glp-1r agonists and uses thereof.
BR112022013746A2 (en) CAGRILINTIDE AQUEOUS FORMULATION, SEMAGLUTIDE AQUEOUS FORMULATION, MEDICAL DEVICE, AND, FIXED DOSE COMBINATION
MX2023008854A (en) Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use.
BR112021022335A2 (en) Crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
SV2017005539A (en) PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
BR112018008805A8 (en) dual-function proteins and pharmaceutical composition comprising the same
BR112015010203A8 (en) composition for the prevention or treatment of diabetes, diabetic complications or diabetes, use of an oxytomodulin analog conjugate, and method for the preparation of an oxytomodulin analog conjugate
CO2023008866A2 (en) Coagonists of glp-1 and amylin receptors
PH12019502655A1 (en) Acylated insulin compound
MX2019008317A (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease.
Forbes et al. Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides
BR112023019967A2 (en) TETRAHYDRONAPHTHALEN COMPOUND AND METHOD OF PREPARATION THEREOF AND USE THEREOF IN MEDICINE
BR112014031649A2 (en) compound represented by formula 1 having activity inhibiting enzyme 11b-hsd1; method for its production and pharmaceutical composition containing the same as active ingredient
BR112022014772A2 (en) Amorphous SOLID DISPERSION, PHARMACEUTICAL COMPOSITION AND PROCESSES FOR THE PREPARATION OF THESE
BR112023020093A2 (en) ANTIBODY-DRUG CONJUGATE, INCLUDING ANTIBODY AGAINST HUMAN CLDN18.2, AND USE THEREOF
AR127945A1 (en) PHARMACEUTICAL FORMULATIONS COMPRISING AN AMYLIN RECEPTOR AGONIST, A GLP-1 RECEPTOR AGONIST AND A CYCLODEXTRIN
Esser et al. Side effects of HIV therapy
CO2024006689A2 (en) Pharmaceutical formulations comprising a cyclodextrin
CL2022003426A1 (en) Levilimab Aqueous Pharmaceutical Composition and Its Use
Carella et al. Hypoglycemia by ginseng in type 2 diabetic patient: case report
MA46778A1 (en) Intranasal composition comprising betahistine
Huerta-Ramos et al. The effect of raloxifene on symptoms and cognitive functioning in a postmenopausal schizophrenia patient: a case report
Rodríguez-Martínez et al. Paliperidone extended-release: safety and tolerability from a metabolic profile perspective
Nowak et al. New therapeutic strategies for Alzheimer’s disease
Syed et al. Fast dispersible tablet of paroxetine hydrochloride: taste masking and administration in depressed patients